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http://www.biomedcentral.com/1471-2407/14/424RESEARCH ARTICLE Open AccessOncogenic Fli-1 is a potential prognostic marker
for the progression of epithelial ovarian cancer
Wei Song1†, Lingyun Hu2†, Wei Li1, Guanjun Wang1, Yan Li1, Lei Yan1, Ailing Li3* and Jiuwei Cui1*Abstract
Background: Ovarian cancer is the most lethal gynecologic malignancy, but its etiology remains poorly
understood. This study investigated the role of Fli-1 in ovarian carcinogenesis and disease survival.
Methods: Fli-1 protein expression was evaluated by immunohistochemistry in 104 primary epithelial ovarian cancer
(EOC) patients with known follow-up data and 20 controls. Correlation between Fli-1 expression and clinical
characteristics was evaluated with the logistic regression. Kaplan Meier analysis was used to assess the impact of
Fli-1 expression on overall survival (OS) and disease-free survival (DFS). Cell proliferation and migration assay
were used to explore the function of Fli-1 in ovarian cancer cells.
Results: Fli-1 was expressed in 74% cases and up-regulated in EOC tissues compared with normal control tissues
(p< 0.05). The high expression of Fli-1 was significantly associated with advanced tumor stage, positive lymph nodal
involvement, and poor OS and DFS (p< 0.05). Further analysis showed Fli-1 is an independent prognostic factor for OS
and DFS. Down-regulation of Fli-1 inhibited cell proliferation but did not affect cell migration in SKOV3 cells.
Conclusions: This study revealed that Fli-1 played an essential role in the development and progression of ovarian
cancers. Its overexpression is intimately related to malignant phenotypes and poor clinical outcome, suggesting
that Fli-1 is a potential prognostic marker and therapeutic molecular target in ovarian cancer.
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Ovarian cancer is the leading cause of death from gyneco-
logic malignancy in developed countries and the second
leading cause in developing countries [1,2]. Epithelial ovar-
ian cancer (EOC) accounts for 90% of ovarian cancers;
however, its aetiology remains unknown. The origin and
pathogenesis of EOC have been investigated but still
poorly understood. Over the past decades, prognosis for
patients with EOC has improved little,with 70–80% of the
cases having a recurrence of the cancer and ultimately
succumbing to the disease [3]. There are a number of
genetic and epigenetic changes that lead to transformation
of ovarian epithelial cells into tumor cells [4]. Recognizing
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unless otherwise stated.identify key molecular regulators in tumorigenesis to
improve the prognosis assessment and treatment of
EOC patients.
Friend leukemia virus integration 1 (Fli-1), a member
of the ETS transcription factor family, is the target of
insertional activation by Friend murine leukemia virus
(F-MuLV) and is preferentially expressed in vascular
endothelial cells and hematopoietic tissues [5,6]. Tran-
scription factors of the ETS family regulate the expres-
sion of oncogenes, tumor suppressor genes, and some
related genes of the vessel’s formation, invasion and me-
tastasis, and often correlate with poor survival in some
types of cancers [7-10]. Fli-1 plays a critical role in nor-
mal development, hematopoiesis and oncogenesis by
functioning as both transcriptional activator and repressor
[11-15]. Knocking-down Fli-1 expression in erythroleu-
kemic cells leads to a marked growth inhibition and cell
death, demonstrating a possible therapeutic approach to
induce tumor suppression [16-19].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic characteristics of EOC patients
Variable Total number %
Age median (range) 52 (22–73)
< 50 43 41














0 mm 76 75
0–10 mm 28 25
CA125 serum level median (range) 263 (19–8410)
≤ 35 U/ml 7 7
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http://www.biomedcentral.com/1471-2407/14/424It has also been shown that Fli-1 maintains several
malignant phenotypes by inhibiting Rb, GATA-1, SHIP-
1 and targeting Bcl-2 [20-22]. Anti-Fli-1 compounds had
been discovered and demonstrated strong anti-leukemic
activity in a mouse erythroleukemia model that overex-
presses Fli-1, making it possible for targeting Fli-1 as a
potent treatment strategy [23].
However, the role of Fli-1 in EOC remains unknown.
Here, we analyzed Fli-1 expression in EOC patients and
studied its function in an ovary cell line.
Methods
Patients and samples
Formalin-fixed paraffin-embedded tissues of ovary and
fallopian tube from primary ovarian cancer patients and
control group, such as uterine prolapse, uterine fibroid
were obtained from the First Hospital of Jilin University
and the General Hospital of Chinese People’s Liberation
Army between 2005 and June 2009. The specimens
included 104 Ovarian Serous Carcinoma, 10 fallopian
tube and 10 normal ovaries. Primitive neuroectodermal
tumor (PNET) was chosen as the positive controls at
the same time. Clinical stage, histological grade and
follow-up data were available for the majority of these
patients. The histological subtypes and disease stages of
the tumors were classified according to International
Federation of Gynecology and Obstetrics (FIGO) criteria.
Approval for the study was obtained from the Research
Ethics Board of the First Hospital of Jilin University and
the General Hospital of Chinese People’s Liberation Army.
The study participants gave their written informed
consent. The clinical characteristics of all patients and
the control group were shown in Table 1. The patients
were followed up for survival analysis.
Immunohistochemistry
Tissue slides were de-paraffinized with xylene and rehy-
drated through a gradual decline of alcohol (100–80%),
and then incubated in 3% hydrogen peroxide for 15
minutes to block endogenous peroxidase activity. Anti-
gen retrieval was carried out by immersing the slides in
10 mM sodium citrate buffer (pH 6.0) and maintained
at a sub-boiling temperature for 15 minutes. The slides
were rinsed in phosphate-buffered saline and incubated
with 10% normal goat serum to block non-specific
staining for 30 minutes at 37°C. Primary anti-Fli-1 poly-
clonal antibodies (Neomarker) were diluted in 1:100, and
incubated with the sections at 4°C overnight. After
washing with PBS, the secondary antibodies (biotinyl-
ated goat anti-rabbit immunoglobulin) and streptavidin
peroxidase complex reagent were applied. Subsequently,
the visualization signal was processed according to
the Polink-2 HRP DAB Detection kit. Finally, the slides
were counterstained with hematoxylin for 15 min anddehydrated in ascending concentrations of alcohol
(80–100%). After xylol treatment, slides were covered.
Two investigators evaluated each stained section inde-
pendently without knowing any clinical information.
The proportions of positive cells were ranged from 10 to
100%, while the intensity of staining was scored as 0
(negative), 1 (weak), 2 (moderate), and 3 (intense) in the
most strongly stained tumor area. The immunoreactivity
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cells multiplied by the intensity of staining.
RNA interference and transfection
Fli-1-specific siRNAs (No. 1 and No. 2) were from Invi-
trogen. The target sequences were 5′-GGGAAAGUUC
ACUGUUGGCCUAUAA-3′ and 5′-AGGAGUGGAUC
AAUCAGCCAGU-GAG-3′, respectively. The target
sequence of control siRNA against photinus pyralis lucif-
erase gene (Invitrogen, CA) was 5′-GGAUUUCGAGUCG
UCUUAAUGUAUA-3′. RNAiMAX transfection reagent
was used for transient transfection following manufac-
turer’s protocol (Invitrogen, CA).
Cell proliferation assay
SKOV3 cells were maintained in DMEM containing 1%
penicillin and streptomycin, supplemented with 10%
fetal bovine serum (FBS), then incubated overnight at
37°C, 5% CO2 with density 10% per well. The number of
cell proliferation was measured by Trypan-blue exclu-
sion assay from day 1 to day 4.
Cell migration and invasion assay
Cell migration and invasion assays were carried out using
Transwell (Corning Costar Corp, MA) membrane filter
inserted in 24-well tissue culture plates (6.5-mm diameter,
8-μm pore size). For migration assay, cells (4 × 104)
suspended in serum-free medium were seeded on the
upper chamber of transwell filters. Serum-containing
medium was added to the lower chamber and incu-
bated for 16 h at 37°C. Nonmigrating cells were re-
moved by wiping the upper side of the filter, and the
remaining cells on the lower surface of the filter were
fixed with 4% formaldehyde, stained with crystal purple
and counted under a microscopy. Each determination
represents the average of three individual experiments.
Immunoblotting and antibodies
Cells were lysed with radioimmunoprecipitation assay
buffer (1% Nonidet P-40, 50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, plus
protease inhibitor cocktail and 1 mM phenylmethylsul-
fonyl fluoride). Proteins were separated by SDS-PAGE
and analyzed by Western blotting. Antibodies to Fli-1
and β-actin were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz Biotechnology, CA, USA).
Cytoplasmic and nuclear fractionation
Cells were harvested by trypsin-EDTA, collected by cen-
trifugation and washed two times in ice-cold PBS. Pellets
were lysed in buffer A containing 10 mM HEPES, pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EDTA, 1 mM PMSF,
1 mM DTT, 1 mM Na3VO4 supplemented with protease
inhibitors and incubated for 15 min on ice. Thereafter,NP-40 was added at a final concentration of 10% and
lysates were oscillated. Nuclei were pelleted by centri-
fugation at 1000 g for 1 min at 4°C and supernatant
containing cytoplasmic proteins (C). The nucleic pel-
lets were lysed in buffer B containing 20 mM HEPES,
pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
PMSF, 1 mM Na3VO4, 1 mM DTT, supplemented with
protease inhibitors by repeated freezing and oscillating.
Supernatants containing soluble nucleic proteins (N)
were collected by centrifugation at 12000 g for 10 min.
Statistical analysis
Statistical analysis was performed by using univariate
(nonparametric rank sum test) and multivariate (logistic
regression) analysis to evaluate the relationship between
gene expression and clinicopathological parameters, in-
cluding age, FIGO stage, histological grade, lymph nodal
involvement, residual tumor size, CA125, ER expression,
PR expression and P53 expression. Disease Free Survival
(DFS) and Overall Survival (OS) were calculated by using
the Kaplan-Meier method, and the differences were
assessed by using the log-rank test. Comparison was made
of groups with high Fli-1 expression (score >median score)
and low Fli-1 expression (score ≤median score). The
nonparametric rank sum test was used to determine the
significance of the difference in the distribution of gene
expression in cancer, borderline and normal samples.
These analyses were performed by SPSS 13.0 Statistical
Software. P ≤ 0.05 was considered as statistically significant.
Result
Oncogenic Fli-1 is up-regulated in ovarian cancer tissues
Immunohistochemical staining revealed that Fli-1 was
generally expressed in the cytoplasm of ovarian cancer
cells with various intensities (Figure 1). In primitive neu-
roectodermal tumor (PNET), Fli-1 was positive in nu-
clear (Figure 1f ). Of the 104 EOC specimens examined
in this study, Fli-1 was positive in 77 (74%) cases. The
scores of intensity were also analyzed. Eight (7.7%) cases
lacked Fli-1 expression; 19 (18.3%) demonstrated weak
expression of Fli-1; 60 (57.7%) demonstrated moderate
expression of Fli-1 and 17 (16.34%) demonstrated a
strong signal. Compared to EOC tissues, Fli-1 expression
was either negative or expressed at negligible amount in
normal ovaries and fallopian tube tissues. The expres-
sion levels of Fli-1 was significantly up-regulated in EOC
tissues compared with normal ovarian (p = 4.56 × 10−5)
and fallopian tube tissues (p = 8.25 × 10−6).
Fli-1 expression is associated with clinicopathological
characteristics of patients with EOC
The expression rates of Fli-1 were 50.0%, 62.4%, 84%
and 83.3% in stage I, II, III and IV, respectively. There
was no difference in the Fli-1 scores of expression level
Figure 1 Fli-1 is highly expressed in ovarian cancer. (a, b, c). Representation of images from immunohistochemical stains Fli-1 in tumors from
three cases of ovarian cancer. (d) Expression of Fli-1 in fallopian tube was negative. (e) Expression of Fli-1 in normal ovarian tissue was negative.
Original magnification × 200. (f) Fli-1 were positive in nuclear in PNET tissues. PNET: Primitive neuroectodermal tumor. (g) Fli-1 expression scores
are shown as box plots, in ovarian cancer, fallopian tube and normal ovarian tissue. with the horizontal lines representing the median; the bottom
and top of the boxes representing the 25th and 75th percentiles, respectively; and the vertical bars representing the range of data.
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IV. However, there was a significant difference between
stageII and stage III (p = 0.036, Figure 2a). Furthermore,the EOC tissues with advanced stage (III ~ IV) showed
high Fli-1 expression more frequently than those with
early stage (I ~ II) (p = 0.000216, Figure 2b).
Figure 2 Inverse correlation between Fli-1 expression and tumor stage. (a) Box plot of Fli-1 expression in tumors with different stage.
(b) Box plot of Fli-1 expression in low stage and advanced stage.
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copathologic parameters analyzed by univariate and
multivariate analysis was illustrated in Table 2. The
expression of Fli-1 was significantly increased in the
group of FIGO stage III and IV, lymph nodal involvement,
and CA125 serum level > 35 U/ml (p < 0.05). However,
Fli-1 expression was not correlated with age, histo-
logical grade, residual tumor size, and the expression of
ER, PR, Her1, Her2 and P53 (p > 0.05).
Fli-1 is a potential prognostic biomarker for ovarian
cancer survival
The median follow-up interval was 32.8 months. Five
patients were lost during follow-up. In univariate sur-
vival analyses for OS and DFS, 99 EOC patients were
divided into two groups based on Fli-1 expression score
in tumors, representing low (scores 0–1.1) and high
(scores > 1.1) expression of Fli-1. The Kaplan Meier sur-
vival curve in Figure 3 confirmed that patients with lowexpression of Fli-1 had better OS (p = 0.030) and DFS
(p = 0.042). The median OS for the high Fli-1 expression
group (48 patients, 33 events) was 27 month; however,
the low Fli-1 expression group had significantly longer
survival (48 months) (51 patients, 25 events). The me-
dian DFS was 23 month for the high Fli-1 expression
group (48 patients, 33 events) but 43 month for the low
Fli-1 expression group (51 patients, 26 events).
Knockdown of Fli-1 inhibits cell proliferation in SKOV3
cells
The cellular localization of Fli-1 was further examined in
SKOV3 cells. The fractionation was verified by the pres-
ence of Lamin A/C in nuclei and tubulin in cytoplasm,
and Fli-1 was present in the cytoplasm (Figure 4a).
Fli-1 was knocked down with target siRNA sequences
in SKOV3 cells and the efficiency was detected by West-
ern blotting (Figure 4b). Initial microscopic observation
and cell counting with Trypan blue showed that the
Table 2 Association between Fli-1 expression and clinicopathological parameters
Parameter p-value (uni) p-value (multi) 95% CI OR
Age at diagnosis 0.848 0.485 0.70-2.13 1.22
< 50 vs≥ 50
FIGO stage < 0.010 < 0.010 0.12-0.52 0.25
≤II vs > II
Histological grade 0.309 0.153 0.18-1.31 0.48
G1 vs G2&G3
Lymph nodal involvement 0.015 < 0.010 0.23-0.80 0.43
Positive vs negative
CA125 serum level 0.006 0.013 0.04-0.68 0.16
≤ 35 U/ml vs > 35 U/ml
Residual tumor size 0.341 0.421 0.41-1.45 0.77
0 mm vs 0-10 mm
ER expression 0.575 0.425 0.46-1.39 0.80
Positive vs negative
PR expression 0.875 0.872 0.60-1.82 1.05
Positive vs negative
Her1 expression 0.228 0.230 0.80-2.58 1.43
Positive vs negative
Her2 expression 0.747 0.518 0.69-2.08 1.20
Positive vs negative
P53 expression 0.586 0.836 0.59-1.94 1.07
Positive vs negative
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nificantly reduced (Figure 4d, p< 0.01). The capability of
migration of SKOV3 cells treated with control siRNA or
Fli-1 siRNA were also examined. As shown in Figure 4c,
knocking-down Fli-1 expression, however, did not have
impact on the migration capacity (p> 0.05).
Discussion
EOC is a very aggressive gynecological tumor. Despite
the use of multimodal therapy, their prognosis remains
poor, with the probability of 5 years survival less than
30% for those presenting with advanced disease [24-26].
The molecular mechanisms involved in EOC remain
largely unknown, and neither was the prediction bio-
marker for prognosis.
The present study is dedicated to identify biomarkers
for prediction and intervention in the tumorigenesis and
development of EOC. To study the association between
Fli-1 and EOC, the expression of Fli-1 in EOC was de-
tected by immunohistochemistry. Approximately 90% of
ES/PNET had a specific t(11; 22)(q24;q12) that results in
fusion of the EWS and FLI-1 genes, and overexpression
of FLI-1 protein. Therefore, PNET was used as positive
control. The expression of Fli-1 in PNET was located
in the nucleus. In contrast, we found that Fli-1 waspredominantly located in the cytoplasm in 74% cases
with various intensities. In recent years, with the full
realization of the genesis for ovarian cancer, it is strongly
suggested that high grade ovarian cancer originates not
from the surface of the ovary, but from the epithelial
layer of the neighboring fallopian tube epithelium [27,28].
Therefore, fallopian tube tissues were taken for control
group together with normal ovaries.
The Fli-1 expression was negative in control group, but
increased in early-stage tumors, and reached the highest
level in advanced stage tumors. Clinicopathologic analysis
of Fli-1 expression revealed that the high expression of
Fli-1 was positively correlated with advanced tumor stage
and positive lymph nodal involvement. This progressively
increased expression profile paralleled with deterioration
of the disease, suggested a role of Fli-1 in progression of
EOC. Although it was shown no significant association
between Fli-1 expression and histological grade, the imbal-
ance in sample size between low grade (G1, 10) and high
grade (G2 and G3, 94) should be considered. At the same
time, the study showed that high expression of biomarker
CA125 was related to the staining of Fli-1, and the signifi-
cance needed to be investigated.
The relationship between Fli-1 expression and progno-
sis was further analyzed by OS and DFS. Patients with
Figure 3 Fli-1 predicts clinical outcome of ovarian cancer. (a, b) Kaplan-Meier estimates of overall survival (a) and disease-free survival
(b) in 99 EOC patients. P value refers to two-sided log-rank tests.
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ing that Fli-1 is an attractive candidate for risk prognos-
tication and the target therapy of EOC. As the treatment
would have impact on survival, we also analyzed the
treatment in the two groups. In this study, all of the
patients were treated with standard regimens. There-
fore, Fli-1 expression is highly associated with the
survival in the patients with ovary cancer.
Increasing expression of Fli-1 is one of the common
scenarios during tumor development and may be associ-
ated with the disease malignancy. To further study the
role of Fli-1 overexpression in growth and metastasis, the
function of Fli-1 in cell line was investigated. Functionally,
we found knocking-down of Fli-1 reduced ovarian cancer
cell proliferation, but did not affect tumor metastasis.
The expression of Fli-1 was predominantly found in
the nuclei of Ewing sarcoma and leukemia [29]. In the
present study, Fli-1 expression was mainly found in the
cytoplasm of ovarian cancer tissues and SKOV3 cells.
These data suggest that Fli-1 is required to function in
the cytoplasm for ovarian cancer. Moreover, previous
studies support that Fli-1 might function through
protein-protein interaction or as being a transcriptionfactor [15,16,30,31]. It was speculated that Fli-1 were
widely expressed in various cancer tissues while it
specifically played different roles. Thus, our results
imply that Fli-1 may have distinct functions in signal
transduction pathways in the cytoplasma, other than
just being transcription factor. The status of Fli-1 in
different cancers and the clinical implications of their
expression during cancer development still need fur-
ther investigation. In addition to the functional study,
further investigation of the molecular mechanisms of
Fli-1 is warranted.
Although invasive epithelial ovarian cancer is widely
seen and treated as a single disease entity, there are differ-
ent histological subtypes. Serous ovarian cancer studied in
this study is the most common subtype. The expression
status of Fli-1 in other subtypes also needs to be investi-
gated in the future.
More importantly, we demonstrate a significant correl-
ation between high Fli-1 immunoreactivity and shorter
overall and disease-free survival. If high Fli-1 expression
can be further confirmed to indicate poor prognosis, as
suggested in this report, it may serve as an important
prognostic marker and an attractive therapeutic target in
Figure 4 Present of Fli-1 and growth characteristics of SKOV3 cells with Fli-1 expression down-regulated. (a) Western blots showing
the purity of the isolated nucleus/cytoplasm sample, nuclear (N) and cytoplasmic (C). (b) SiRNA transfection efficiency in tumor cells was
measured by Western blotting; (c) Transwell migration assay of the indicated cell lines transfected with Fli-1 constructs or transient
transfected with two different Fli-1 siRNA target sequence. (d) The growth curve displays the absolute counts of cells cultured in twelve-well plates
during the 4-day treatment.
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sample size, and it is a retrospective and monocentric
study. Therefore, further larger, multicentric studies are
needed.Conclusion
In conclusion, our findings suggest that Fli-1 is an im-
portant molecular change significantly related to tumori-
genesis and progression of EOC. However, a larger
Song et al. BMC Cancer 2014, 14:424 Page 9 of 9
http://www.biomedcentral.com/1471-2407/14/424cohort of patients with ovarian cancer and other cancer
types is still required to further define the clinical signifi-
cance of Fli-1 and its prognostic value in ovarian cancers
in the future.
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